These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2533899)

  • 21. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
    Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
    Mabro M; Granisétron PK
    Bull Cancer; 1999 Mar; 86(3):295-301. PubMed ID: 10210764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
    Csáki C; Ferencz T; Koós R; Schuler D; Borsi J
    Orv Hetil; 1993 Jun; 134(25):1363-7. PubMed ID: 8332356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial].
    Zeng W; Zhou J; Zhang P
    Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):294-7. PubMed ID: 7587900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.
    Spitzer TR; Friedman CJ; Bushnell W; Frankel SR; Raschko J
    Bone Marrow Transplant; 2000 Jul; 26(2):203-10. PubMed ID: 10918432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study.
    Einarson A; Maltepe C; Navioz Y; Kennedy D; Tan MP; Koren G
    BJOG; 2004 Sep; 111(9):940-3. PubMed ID: 15327608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three reports at ASCO show ondansetron to be a very effective antiemetic with few side effects.
    Oncology (Williston Park); 1990 Sep; 4(9):98, 102. PubMed ID: 2145023
    [No Abstract]   [Full Text] [Related]  

  • 29. Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
    Matera MG; Di Tullio M; Lucarelli C; Casale F; Calabria C; Lampa E; Indolfi P; Rossi F
    J Med; 1993; 24(2-3):161-70. PubMed ID: 7691978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
    Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
    Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
    Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
    Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
    Shi Y; He X; Yang S; Ai B; Zhang C; Huang D; Dong M; Liu P; Zhou S; Han X
    Chemotherapy; 2007; 53(1):44-50. PubMed ID: 17202811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ondansetron: confusing documentation surrounding an extrapyramidal reaction.
    Kanarek BB; Curnow R; Palmer J; Cook SF
    J Clin Oncol; 1992 Mar; 10(3):506-7. PubMed ID: 1531497
    [No Abstract]   [Full Text] [Related]  

  • 34. Proceedings of the Ondansetron Symposium. London, 30 June 1989.
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S1-93. PubMed ID: 2533893
    [No Abstract]   [Full Text] [Related]  

  • 35. Ondansetron, important new antiemetic, approved by FDA.
    Oncology (Williston Park); 1991 Mar; 5(3):12. PubMed ID: 1829939
    [No Abstract]   [Full Text] [Related]  

  • 36. Extrapyramidal reaction caused by ondansetron.
    Dobrow RB; Coppock MA; Hosenpud JR
    J Clin Oncol; 1991 Oct; 9(10):1921. PubMed ID: 1833512
    [No Abstract]   [Full Text] [Related]  

  • 37. Extrapyramidal reaction to ondansetron.
    Halperin JR; Murphy B
    Cancer; 1992 Mar; 69(5):1275. PubMed ID: 1531444
    [No Abstract]   [Full Text] [Related]  

  • 38. Ondansetron in the treatment of theophylline overdose.
    Brown SG; Prentice DA
    Med J Aust; 1992 Apr; 156(7):512. PubMed ID: 1532627
    [No Abstract]   [Full Text] [Related]  

  • 39. Ondansetron Hypersensitivity: A Clinical Diagnosis Protocol and Cross-Reactivity Study.
    García Núñez I; Algaba Mármol MA; Reina Ariza E
    J Investig Allergol Clin Immunol; 2015; 25(3):221-2. PubMed ID: 26182691
    [No Abstract]   [Full Text] [Related]  

  • 40. Using ondansetron with pediatric patients undergoing total body irradiation.
    Witherow P; Wilson K
    Oncol Nurs Forum; 1991; 18(8):1416-7. PubMed ID: 1837082
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.